Basic Information
LncRNA/CircRNA Name | HANR |
Synonyms | NA |
Region | NA |
Ensemble | NA |
Refseq | NA |
Classification Information
Regulatory Mechanism | Biological Function | Clinical Application | |||
---|---|---|---|---|---|
TF | Immune | Survival | |||
Enhancer | Apoptosis | Drug | |||
Variant | Cell Growth | Circulating | |||
MiRNA | EMT | Metastasis | |||
Methylation | Coding Ability | Recurrence |
Cancer&Entry Information
Cancer Name | hepatocellular carcinoma |
ICD-0-3 | C22.0 |
Methods | qRT-PC, Luciferase reporter assay, other |
Sample | HCC tissues and cell line(HepG2) |
Expression Pattern | up-regulated |
Function Description | esides, HANR knockdown induces attenuated cell proliferation, migration, invasion of HCC cells. By bioinformatic analysis and dual luciferase reporter assay, we found that miR-214 was the downstream target of HANR. Furthermore, miR-214 inhibitor largely enhanced tumor phenotypes of HCC cells regulated by HANR knockdown. HANR and miR-214 regulated the EZH2, then affecting TGFBR2 level. Finally, we demonstrated that EZH2 overexpression could greatly rescue HANR knockdown or miR-214 mimic-induced HCC tumorigenesis and progression. |
Pubmed ID | 30342849 |
Year | 2018 |
Title | HANR Promotes Hepatocellular Carcinoma Progression via miR-214/EZH2/TGF-? Axis |
External Links
Links for HANR | GenBank HGNC NONCODE |
Links for hepatocellular carcinoma | OMIM COSMIC |